ArticleFrontiers in oncology2026
SULT1A1 at a differentiation branch point regulates osteosarcoma cell proliferation and melatonin-mediated anti-tumor activity.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circadian disruption is increasingly recognized as a contributing factor in tumorigenesis and tumor evolution; however, the role of circadian genes in osteosarcoma cell fate determination and therapeutic response remains to be fully elucidated. Methods: Gene expression data from GEO were integrated to construct a prognostic model of circadian rhythm-annotated genes based on melatonin-related signatures, validated using the TARGET database. Single-cell RNA-seq and pseudotime trajectory inference were performed to characterize osteosarcoma cell states and identify branch-point genes. We queried publicly available CRISPR-Cas9 dependency data (DepMap) and performed functional assays in osteosarcoma cell lines. Results: A five-gene circadian rhythm-annotated prognostic signature was established and validated. The intersection of the signature with branch-point genes and circadian rhythm-annotated genes identified Conclusions: Our findings identify
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.